Evidence map›Paper›PMID 36974559›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

Study on Breast Cancer in Kazakhstan Using the Functional Time Series.

Adiya Shertaeva, Dinara Ospanova, Andrej Grjibovsky, Alfia Shamsutdinova, Nurlan Rakhmetov, Zaure Dushimova, Bagdat Salimgereeva, Zhannym Yermentayeva, Indira Kaketaeva, Yerlan Kuandykov and 3 more

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Adiya ShertaevaS.D. Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Dinara OspanovaAl-Farabi Kazakh National l University, Almaty, Republic of Kazakhstan.
Andrej GrjibovskyNorthern State Medical University, Arkhangelsk, Russian Federation.
Alfia ShamsutdinovaCentral Clinical Hospital, Almaty, Republic of Kazakhstan.
Nurlan RakhmetovS.D. Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Zaure DushimovaKazakh Research Institute of Oncology and Radiology Almaty, Republic of Kazakhstan.
Bagdat SalimgereevaKazakh-Russian Medical University, Almaty, Republic of Kazakhstan.
Zhannym YermentayevaKazakh-Russian Medical University, Almaty, Republic of Kazakhstan.
Indira KaketaevaKazakh-Russian Medical University, Almaty, Republic of Kazakhstan.
Yerlan KuandykovKhoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent Medical Institute Postgraduate Studies Faculty, Shymkent, Republic of Kazakhstan.
Shynar TanabayevaS.D. Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Ildar FakhradiyevS.D. Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.ORCID https://orcid.org/00
Samat ZharmenovKazakhstan's Medical University "Kazakhstan School of Public Health", Almaty, Republic of Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIn Kazakhstan and Central Asia, breast cancer (BC) is the most common malignancy among women. However, no large-scale study on breast cancer using the functional time series approach has been carried out in Kazakhstan.

methodsA functional assessment of the age-period-cohort model (APC) and the survival rate (period 2017-2021) was used in the retrospective study. Clinical and demographic information on patients was analysed, including age, gender, region of residence, kind and stage of tumour, occupation, socioeconomic standing, nationality, and specifics of treatment and its outcomes. Additionally, the relationship between nationality, stage, and residency region and the survival rate of breast cancer patients was investigated too.

resultsThe data of n=22,736 breast cancer patients were analysed. The highest number of breast cancer cases reported was 4,945 (21.7%), in 2019. In 2021, n =4,939 (21.7%) cases were detected, while in 2020, n=4,222 (18.6%) cases were observed. The patients with breast cancer in stages I and Ia were recognized in 6,585 (29% of cases), while those in stages Ib and Ic were confirmed in 8687 (38.2% of cases). In n=10,147 (44.6%) cases, a malignant tumour of the upper outer quadrant of the breast (C50.4) was predominant. Kazakhs made up the majority (n=10,939, 48.1%) of patients with a primary validated diagnosis of breast cancer, followed by Russians (n=7527, 33.1%). Germans had the lowest survival rate overall (11.4 ± 1.7 months) (p ≤ 0.05) (95% CI: 8.0-14.7 months). Uzbeks showed relatively high survival rates of 18.3 ± 1.6 months (95% CI: 15.1-21.5 months) (p ≤ 0.05). The Aktobe region had the lowest breast cancer survival rates, measuring 12.1±0.9 months (95% CI: 10.3-13.9 months) (p ≤ 0.05). The highest survival rates, 18.0±1.3 months (95% CI: 15.5-20.5 months) and 17.9±1.4 months (95% CI: 15.3-20.7 months), were seen in Shymkent and Zhambyl regions (p ≤ 0.05), respectively. The prevalence of breast cancer increases after 37.5 years, according to the results of the APC analysis, with an indicator of 0.572 (95% CI: -0.41 - 1.56), maintaining a steady upward trend in the age range from 42.5 years to 62.5 years.

conclusionsDespite a slight drop in the disease's frequency, the incidence of breast cancer in women 37.5 years and older has been stable over the past five years. Additionally, it was shown that the country's northern regions had a higher incidence of breast cancer cases than the southern and western regions. Our results show the significance of demographic characteristics such as age and location for the development of preventive measures and effective treatment.

Indexed as

Breast NeoplasmsAdultFemaleHumansIncidenceKazakhstanRetrospective StudiesTime Factorsbreast cancerEpidemiologyethnicityPrevalencesurvival

Identifiers

PMID36974559
PMCPMC10334077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.